A Study of LY4257496 in Participants With Cancer (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks o

Trial Details

NCT ID
NCT07114601
Phase
PHASE1
Sponsor
Eli Lilly and Company
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • LY4257496
  • Standard of Care Anticancer Therapies
  • LY4257529
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Santa Monica, California, United States|34.01949,-118.49138
  • Stanford, California, United States|37.42411,-122.16608
  • Miami, Florida, United States|25.77427,-80.19366
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.
  • Must be assessed by computed tomography (CT)/magnetic resonance imaging (MRI) to confirm at least 1 of the following:
  • At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to repre…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →